• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [15931 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2014 Health Quality Ontario (HQO) Effect of supportive interventions on informal caregivers of people at the end of life: a rapid review
2014 The HTA Center of the Stockholm County Council/Gotland [Wound infections after surgery-effect of triclosan-coated sutures]
2014 The HTA Center of the Stockholm County Council/Gotland [Superficial wound infections after colorectal surgery and appendectomy-favourable effect of Alexis wound edge protector]
2014 Adelaide Health Technology Assessment (AHTA) Catheter-free (wireless) ambulatory oesophageal pH monitoring for gastro-oesophageal reflux disease (GORD)
2014 Adelaide Health Technology Assessment (AHTA) Bone mineral density analyses using dual energy x-ray absorptiometry (DXA) for women in their 50th year
2014 Adelaide Health Technology Assessment (AHTA) Computed tomography colonography for the diagnosis or exclusion of colorectal neoplasia
2014 Adelaide Health Technology Assessment (AHTA) HbA1c testing in the diagnosis of diabetes mellitus
2014 Adelaide Health Technology Assessment (AHTA) Retinal photography with a non-mydriatic retinal camera in people with diabetes
2014 NIHR Horizon Scanning Centre (NIHR HSC) Idelalisib (Zydelig) for relapsed chronic lymphocytic leukaemia – in combination with bendamustine and rituximab
2014 NIHR Horizon Scanning Centre (NIHR HSC) Ipilimumab (Yervoy) for metastatic hormone-relapsed prostate cancer following docetaxel treatment and radiotherapy
2014 NIHR Horizon Scanning Centre (NIHR HSC) Lanreotide for unresectable, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumours – first line
2014 NIHR Horizon Scanning Centre (NIHR HSC) Nivolumab for advanced melanoma – second or third line
2014 NIHR Horizon Scanning Centre (NIHR HSC) Nivolumab for BRAF V600 mutation– negative advanced melanoma – first line
2014 NIHR Horizon Scanning Centre (NIHR HSC) Nivolumab for BRAF V600 mutation-positive advanced melanoma – first line
2014 NIHR Horizon Scanning Centre (NIHR HSC) Nivolumab with ipilimumab for advanced melanoma – first line
2014 NIHR Horizon Scanning Centre (NIHR HSC) Nivolumab for advanced or metastatic clear-cell renal cell carcinoma – second or third line
2014 NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab (Cyramza) in combination with docetaxel for locally advanced or metastatic non-small cell lung cancer – second line
2014 NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab for metastatic colorectal cancer – second line
2014 NIHR Horizon Scanning Centre (NIHR HSC) Tasquinimod for chemotherapy naïve, metastatic hormone-relapsed prostate cancer
2014 NIHR Horizon Scanning Centre (NIHR HSC) TH-302 in combination with doxorubicin for locally advanced or metastatic, unresectable soft tissue sarcoma – first line
2014 NIHR Horizon Scanning Centre (NIHR HSC) SpaceOAR® perirectal spacing system for prostate cancer radiation
2014 NIHR Horizon Scanning Centre (NIHR HSC) Macy catheter for rectal drug administration
2014 NIHR Horizon Scanning Centre (NIHR HSC) CoVa™ Monitoring System for congestive heart failure
2014 NIHR Horizon Scanning Centre (NIHR HSC) Kangaroo™ feeding tube with IRIS technology for aid in nasogastric tube placement
2014 NIHR Horizon Scanning Centre (NIHR HSC) Aflibercept solution (Eylea) for visual impairment due to macular oedema secondary to branch retinal vein occlusion
2014 NIHR Horizon Scanning Centre (NIHR HSC) SoftVue™ system for diagnostic breast imaging
2014 NIHR Horizon Scanning Centre (NIHR HSC) Collagenase Clostridium histolyticum (Xiapex) for Peyronie's disease – first line
2014 NIHR Horizon Scanning Centre (NIHR HSC) Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects
2014 NIHR Horizon Scanning Centre (NIHR HSC) Alpha-1 antitrypsin (Respreeza) for emphysema associated with alpha-1 antitrypsin deficiency – maintenance therapy
2014 NIHR Horizon Scanning Centre (NIHR HSC) Adalimumab (Humira) for severe chronic plaque psoriasis in children and adolescents – second line
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Routine ordering of primary pathology examinations in Canada
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Couples therapy for adults experiencing relationship distress: a review of the clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Compression therapy in diabetic foot ulcer management: a review of clinical effectiveness, cost-effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Initiatives to optimize the utilization of laboratory tests
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) HbA1c testing frequency: a review of the clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) The use of the electromotive drug administration system in patients with overactive bladder: a review of the clinical effectiveness, safety, and cost-effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Botulinum toxin A for myofascial pain syndrome: a review of the clinical effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) The use of the electromotive drug administration system in patients with superficial bladder cancer: a review of the clinical effectiveness, safety, and cost-effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Hydroxyethyl starch use for patients with postpartum hemorrhage: a review of clinical effectiveness, safety, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Debridement procedures for managing diabetic foot ulcers: a review of clinical effectiveness, cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Nabilone for non-chemotherapy-associated nausea and weight loss due to medical conditions: a review of the clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Drug therapy for chronic thromboembolic pulmonary hypertension: a review of the comparative clinical effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Infection prevention and control procedures for carbapenemase-producing Enterobacteriaceae: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Obstetric, neonatal, and child outcomes for women with previous bariatric surgery: a review of the clinical evidence
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Essential oil products for disinfection: clinical effectiveness, cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Aripiprazole (Abilify — Bristol-Myers Squibb Canada) new indication: major depressive disorder
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Ustekinumab (Stelara — Janssen Inc.) indication: psoriatic arthritis
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Aflibercept (Eylea — Bayer Inc.) indication: wet age-related macular degeneration
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Stiripentol (Diacomit — Biocodex SA) indication: severe myoclonic epilepsy in infancy (Dravet syndrome)
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Guanfacine hydrochloride extended release (Intuniv XR — Shire Canada Inc.) indication: attention deficit hyperactivity disorder
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Timothy grass standardized allergenic extract (Grastek — Merck Canada Inc.) indication: allergic rhinitis (grass pollen)
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Fluticasone furoate /vilanterol (Breo Ellipta — GlaxoSmithKline) indication: chronic obstructive pulmonary disease
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Dolutegravir (Tivicay — ViiV Healthcare ULC) indication: HIV infection
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Nephrostomy and biliary tube management: a review of the clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Natural sheepskins for the treatment of pressure ulcers: clinical effectiveness, cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Regular health monitoring for older adults: clinical evidence
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Golimumab (Simponi IV — Janssen Inc.) indication: rheumatoid arthritis
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Riociguat (Adempas — Bayer HealthCare) indication: chronic thromboembolic pulmonary hypertension
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Use of azathioprine in adults: safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Negative pressure wound therapy for managing diabetic foot ulcers: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Virtual reality exposure therapy for adults with post-traumatic stress disorder: a review of the clinical effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Hyperbaric oxygen therapy for adults with mental illness: a review of the clinical effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Normothermia versus therapeutic hypothermia for adult patients after cardiac arrest: clinical evidence
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Growth measurement of infants and children: guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Neurofeedback and biofeedback for mood and anxiety disorders: a review of the clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Admission of patients with suspected or active infection to oncology units: clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Breast reduction surgery for hypermastia: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Endovascular thermal ablation technologies for treatment of varicose veins: a review of clinical effectiveness, safety, cost-effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Wear compliance and donning/doffing of respiratory protection for bioaerosols or infectious agents: a review of the effectiveness, safety, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Respiratory precautions for protection from bioaerosols or infectious agents: a review of the clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Motor interventions for autism spectrum disorder in children: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Oral ginger for the management of chemotherapy-induced nausea and vomiting in pediatric patients: clinical effectiveness and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Long-term use of bevacizumab for the treatment of age-related macular degeneration: safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Methylene blue for the prevention and treatment of ifosfamide-induced encephalopathy: clinical effectiveness and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Nasogastric feeding tubes versus percutaneous endoscopic gastrostomy for patients with head or neck cancer: a review of clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Thrombophilia testing for women who have had pregnancy loss: clinical evidence, cost-effectiveness, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Bone marrow aspiration or biopsy for patients with immune thrombocytopenia: clinical evidence
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Patient-controlled analgesia for acute injury transfers: a review of the clinical effectiveness, safety, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Ondansetron for post-operative nausea and vomiting in elderly patients: clinical effectiveness and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Hand sanitizers for the prevention of infection transmission: comparative clinical effectiveness and clinical evidence
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Cardiopulmonary resuscitation for elderly adults in chronic or long-term care: clinical effectiveness and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Cataract surgery performed under local anaesthesia: guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Medical marijuana for the treatment of mental illness: clinical evidence
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Immersion in water during active labour and delivery: clinical effectiveness, safety, and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Short- and long-term use of benzodiazepines in patients with generalized anxiety disorder: a review of guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Simethicone administration during endoscopic procedures: clinical evidence and guidelines
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Saxagliptin + metformin (Komboglyze — AstraZeneca) indication: type 2 diabetes mellitus
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Simeprevir (Galexos — Janssen Inc.) indication: chronic hepatitis C genotype 1 infection
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Aclidinium bromide (Tudorza Genuair — Almirall Canada Ltd.) indication: chronic obstructive pulmonary disease